RE:RE:PanCan's Precision Promise adaptive clinical trial programONCY has also been granted PanCansTherapeutic Accelerator Award (TAA). To achieve this, ONCY was competitively selected for the TAA which provides grants of up to $5 million to incentivize pharma and biotech companies to prioritize new pancreatic cancer therapies and conduct early-stage (Phase 1 and 2) clinical trials for these therapies.